Format

Send to

Choose Destination
Recent Pat Anticancer Drug Discov. 2012 May 1;7(2):168-84.

Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential.

Author information

1
Institute of Translational Medicine & Department of Laboratory Medicine, The First People's Hospital of Chenzhou, Chenzhou, Hunan, PR China.

Abstract

Acetyl-CoA carboxylases (ACCs) play a rate-limiting role in fatty acid biosynthesis in plants, microbes, mammals and humans. ACCs have the activity of both biotin carboxylase (BC) and carboxyltransferase (CT), catalyzing carboxylation of Acetyl-CoA to malonyl-CoA. In the past years, ACCs have been used as targets for herbicides in agriculture and for drug discovery and development of human diseases, such as microbial infections, diabetes, obesity and cancer. A great number of small molecule ACC inhibitors have been developed, including natural and non-natural (artificial) products. These chemicals target BC reaction, CT reaction or ACC phosphorylation. This article provides a comprehensive review and updates of ACC inhibitors, with a focus on their therapeutic application in metabolic syndromes and malignant diseases. The patent status of common ACC inhibitors is discussed.

PMID:
22339356
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center